Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTEAse inhibitor (darunavir/ritonavir) in mono- or triple therapy in suppressed HIV-1 infected subjects
2011-001635-23Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of darunavir and ritonavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Virological suppression at week 48. Started Jul 2011; status: completed.
02
Drugs
darunavirritonavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2011-001635-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001635-23.